ACTEMRA IV has been studied in a number of children with polyarticular JIA (PJIA). The CHERISH study was done over a 2-year period and showed that:
*Most patients were taking methotrexate with ACTEMRA during clinical trials.
ACTEMRA was proven to reduce disease flare-ups in children living with PJIA.
Only about 1 out of 4 children still had disease flares between 16 and 40 weeks of treatment with ACTEMRA.
In contrast, almost 2 out of 4 children not taking ACTEMRA had disease flares in the same period.
Some people have experienced serious life-threatening liver problems, which required liver transplant or led to death. Your healthcare provider may tell you to stop taking ACTEMRA if you develop new or worsening liver problems during treatment with ACTEMRA. Tell your healthcare provider right away if you have any of the following symptoms:
Please see Important Safety and Side Effect Information. For additional Important Safety Information, please see full Prescribing Information, including BOXED WARNING and Medication Guide.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.